These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1543018)

  • 1. Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist.
    Dale PO; Tanbo T; Djøseland O; Jervell J; Abyholm T
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):132-6. PubMed ID: 1543018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
    Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide.
    Lasco A; Cucinotta D; Gigante A; Denuzzo G; Pedulla M; Trifiletti A; Frisina N
    Eur J Endocrinol; 1995 Dec; 133(6):718-22. PubMed ID: 8548057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels.
    Tropeano G; Vuolo IP; Lucisano A; Liberale L; Barini A; Carfagna P; Caroli G; Menini E; dell'Acqua S
    J Endocrinol Invest; 1996 Mar; 19(3):139-45. PubMed ID: 8743278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
    Nestler JE; Powers LP; Matt DW; Steingold KA; Plymate SR; Rittmaster RS; Clore JN; Blackard WG
    J Clin Endocrinol Metab; 1991 Jan; 72(1):83-9. PubMed ID: 1898744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
    Sahin Y; Ayata D; Keleştimur F
    Eur J Endocrinol; 1997 Apr; 136(4):410-5. PubMed ID: 9150702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.
    Nestler JE; Barlascini CO; Matt DW; Steingold KA; Plymate SR; Clore JN; Blackard WG
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1027-32. PubMed ID: 2498378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist.
    Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S
    Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome.
    Macleod AF; Wheeler MJ; Gordon P; Lowy C; Sönksen PH; Conaglen JV
    J Endocrinol; 1990 May; 125(2):317-25. PubMed ID: 2115566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.
    Dale PO; Tanbo T; Vaaler S; Abyholm T
    Fertil Steril; 1992 Sep; 58(3):487-91. PubMed ID: 1521640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F; Hatala DA; Speroff L
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of LH suppression in polycystic ovary syndrome.
    Fleming R; Black WP; Coutts JR
    Clin Endocrinol (Oxf); 1985 Dec; 23(6):683-8. PubMed ID: 3938353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin.
    Cibula D; Sindelka G; Hill M; Fanta M; Skrha J; Zivny J
    Hum Reprod; 2002 Jan; 17(1):76-82. PubMed ID: 11756365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Tosi F; Negri C; Perrone F; Dorizzi R; Castello R; Bonora E; Moghetti P
    J Clin Endocrinol Metab; 2012 May; 97(5):1712-9. PubMed ID: 22419715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.